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Abstract
Background: Profiling the somatic mutations of genes which may inform about tumor evolution, prognostics and
treatment is becoming a standard tool in clinical oncology. Commercially available cancer gene panels rely on
manually gathered cancer-related genes, in a “one-size-fits-many” solution. The design of new panels requires
laborious search of literature and cancer genomics resources, with their performance on cohorts of patients difficult
to estimate.
Results: We present OncoPaD, to our knowledge the first tool aimed at the rational design of cancer gene panels.
OncoPaD estimates the cost-effectiveness of the designed panel on a cohort of tumors and provides reports on the
importance of individual mutations for tumorigenesis or therapy. With a friendly interface and intuitive input,
OncoPaD suggests researchers relevant sets of genes to be included in the panel, because prior knowledge or
analyses indicate that their mutations either drive tumorigenesis or function as biomarkers of drug response.
OncoPaD also provides reports on the importance of individual mutations for tumorigenesis or therapy that
support the interpretation of the results obtained with the designed panel. We demonstrate in silico that OncoPaD
designed panels are more cost-effective—i.e. detect a maximum fraction of tumors in the cohort by sequencing a
minimum quantity of DNA—than available panels.
Conclusions: With its unique features, OncoPaD will help clinicians and researchers design tailored next-generating
sequencing (NGS) panels to detect circulating tumor DNA or biopsy specimens, thereby facilitating early and accurate
detection of tumors, genomics informed therapeutic decisions, patient follow-up and timely identification of resistance
mechanisms to targeted agents. OncoPaD may be accessed through http://www.intogen.org/oncopad.
Keywords: Cancer panels, Panels cost-effectiveness, Rational design of panels, Tumor early detection, Drug profiling of
tumor cohorts, Cancer driver genes, Anti-cancer drug response biomarkers
Background
Profiling somatic mutations in the coding sequence of
genes that have predictive, prognostic or diagnostic value
is becoming a standard tool in clinical oncology [1, 2].
Gene panels present advantages with respect to whole-
exome sequencing in the clinical and translational re-
search settings that extend beyond cost-effectiveness.
For example, they possess a higher sensitivity to detect var-
iants and are less prone to the detection of false-positive
somatic mutations [3], which are key requirements if mu-
tations detected via gene panels sequencing are going to be
used to guide targeted cancer therapies or for early cancer
screening via liquid biopsies [4].
Several commercial solutions are currently available to
meet the growing need of cancer gene panels. All these
currently available commercial and in-house cancer gene
panels rely on manually gathered cancer-related genes
and/or alterations that are known biomarkers of sensitivity
or resistance to targeted agents, and constitute “one-size-
fits-many” solutions. In both translational and basic inves-
tigation, researchers may need to design gene panels spe-
cifically tailored for particular questions (see, for example
[1, 5, 6]). The design of specific panels requires laborious
search of the literature and cancer genomics resources.
Furthermore, whether the panel chosen comes from a
commercial source or is designed by the researcher, it is
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very difficult to estimate its cost-effectiveness on a cohort
of cancer patients.
Our previous systematic analysis of large cancer co-
horts [7], which produced comprehensive catalogs of
driver genes [8] across 28 cancer types, together with an
in-house expert-curated compilation of tumor alter-
ations, relevant to tumorigenesis or influencing drug ef-
fect, provide an opportunity to solve the aforementioned
hurdles. Here, we present OncoPaD (http://intogen.org/
oncopad), to our knowledge the first web-based tool
aimed at the rational design of cancer gene panels,
which dynamically estimates their cost-effectiveness to
profile large cohorts of tumors of 28 cancer types.
Methods
Cancer cohort data
Mutational cancer data were obtained from the cohort
of 6792 samples from 28 cancer types collected by
Rubio-Perez and Tamborero et al. [8], see reference for
details on data collection. We added a cohort of 506
chronic lymphocytic leukemias (CLL) from Puente et al. [9]
A panel can be designed to profile any of the 28 can-
cer types (i.e. a comprehensive solid and hematologic
panel), for a group of them (e.g. a panel only for
hematologic malignancies or for lung carcinomas) or for
an individual cancer type (e.g. a panel for breast cancer).
Additional file 1: Table S1 presents a list of all cohorts
included and cohort groups pre-built in OncoPaD.
Integrating lists of known cancer driver genes
We prepared four lists of interesting genes as input can-
didates for panel design:
(1)The Cancer Drivers Database (http://www.intogen.
org/downloads; 2014.12) [8] of genes driving
tumorigenesis of cohorts of 28 cancer types.
(2)The Cancer Gene Census [10].
(3)Genes with validated oncogenic mutations in
specific cancer types from a manual in-house
compilation (see below).
(4)Specific CLL (underrepresented in the cohorts in
(1)) drivers from Puente et al. [9].
We integrated these four lists into a complete and reli-
able catalog of cancer driver genes as input of OncoPaD.
Although the four lists have several genes in common, they
are complementary as each of them is generated through a
different approach (see Additional file 2: Supplementary
Methods for more details; Additional file 3: Table S2 con-
tains the driver genes comprised in each list).
Prioritization of panel candidates
OncoPaD computes the cumulative mutational frequency
(CMF) of the panel in the cohort of the tumor type(s)
selected by the user as the number of tumors bearing
protein-affecting mutations (PAMs; see Additional file 2:
Supplementary Methods for details on mutations consid-




item : gene or gene hotspot
The tool also calculates two additional CMFs to com-
pute the coverage of tumors with two or three mutations
in the genes within the panel. The elements in the panel
are ranked according to their contribution to the in-
crease of the CMF. OncoPaD computes the regression
line of the CMF distribution and identifies three tiers of
candidate items to include in the panel (see Additional
file 2: Supplementary Methods for details):
(1)Tier 1 candidates: genes and/or mutational hotspots
that contribute the most to the slope of the CMF
distribution, i.e. to the mutational coverage of the panel.
(2)Tier 2 candidates: their contribution to the CMF
distribution is smaller than that of genes and/or
mutational hotspots of Tier 1.
(3)Tier 3 candidates: all other genes and/or mutational
hotspots included in the panel. Their contribution to
the coverage of the panel is negligible.
Tier 1 candidates are preferred to design the panel.
Tier 2 candidates may be included if maximum coverage
of the mutations in the cohort is desired, although their
inclusion may reduce sequencing depth. The users may
fine-tune Tier 1 candidates if they comprise a long list
using the Tier 1 stringent classification option (see
Additional file 2: Supplementary Methods).
Identification of hotspots with high density of mutations
We designed a simple algorithm for the identification of
mutational hotspots. Briefly, it iteratively identifies the
minimum number of base pairs regions (of at most
100 bps) across the sequence of the gene that contain
most of its mutations (see below). In each iteration the
hotspot with the highest number of mutations is identi-
fied. Its mutations are then removed from the gene be-
fore the following iteration. The search stops when all
sites left in the gene contain fewer than two mutations.
After all hotspots are identified, the algorithm checks
whether all hotspots identified account for at least a
minimum fraction of all the mutations in the gene (set
at 80 % by default, but configurable by the user). If this
is the case, all identified hotspots are incorporated indi-
vidually into the panel (see Additional file 2: Figure S1);
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else, the complete exome of the gene is incorporated
into the panel.
Resources used to annotate mutations and genes in the
panel
To provide the designer of the panel ancillary information
on relevant mutations associated to tumorigenesis or re-
sponse to anti-cancer drugs we have retrieved information
from the following sources (see details in Additional file 2:
Supplementary Methods):
(1)A list of validated oncogenic mutations, obtained
from the catalog of driver mutations of Tamborero
et al. (in preparation, available at www.intogen.org/
downloads), which contains somatic and germline
mutations whose role in oncogenesis has been
experimentally validated in different cancer types.
(2)A list of mutations known to predict sensitivity or
resistance to anti-cancer drugs, obtained from the
Cancer bioMarkers database by Tamborero et al.
(in preparation, available at https://www.cancergen-
omeinterpreter.org/biomarkers), which contains
expert curated annotations of genomics biomarkers
associated to a drug effect on tumors, either drug
“response” or “resistance.”
At gene level, OncoPaD adds information regarding the
mode of action of the gene in cancer (i.e. a prediction on
whether it acts through loss of function or activation) and
the tendency of mutations in the gene to occur in the
major clone in specific cancer type(s) according to the
Cancer Drivers Database [8]. Data retrieved from all afore-
mentioned resources will be continuously updated as new
releases become available.
Design and implementation of the OncoPaD web service
OncoPaD imposes no computational burden on its users
beyond the employment of a reasonably modern web
browser; no browser plugins are needed. The users are
required to register using the Mozilla Persona service
just to keep track of the visits and jobs run at the server.
The OncoPaD web service is implemented in Python 3
and relies on the CherryPy web framework [11]. The
reports of the results of the panel use several Javascript
resources, such as the Highcharts [12] line plots to repre-
sent the mutational coverage, and the Mutations Needle
Plot [13] to represent the distribution of mutations across
the protein sequence of a gene. All reports may be down-
loaded as a PDF file, including all charts and tables, and
the genomic location of the panel candidates can be down-
loaded in a BED file. The complete web service implemen-
tation is available for download to academia at https://
bitbucket.org/bbglab/oncopad under an ad hoc Free
Source Code License Agreement.
Results and discussion
OncoPaD is a tool for the rational design of gene panels
OncoPaD builds upon systematic analyses of large tumor
cohorts comprising 7298 samples [7–9, 14] to produce a
comprehensive catalog of mutational drivers specific for
28 cancer types. The first input of OncoPaD is the list of
(1) mutational drivers of one or more tumor types and
well-known cancer genes [10], (2) manually collected
driver genes bearing alterations known to influence anti-
tumor drug effects (biomarkers maintained in an in-
house database), or (3) user-defined genes of interest
(Fig. 1). The choice of a specific tumor type(s) triggers
the selection of the specific list of driver genes and a
subset (panel cohort) of tumors from the initial 7298
samples pan-cancer cohort. While the list of driver genes
is then employed to carry out the design of the panel,
the panel cohort serves the purpose to fine-tune its cost-
effectiveness (Fig. 1, panels 1, 2, and 4). OncoPaD first
uses the pattern of mutations observed in the sequence
of each input gene across the tumors of the panel co-
hort, to identify mutational hotspots that accumulate the
majority of the mutations detected in the gene (Fig. 1,
panel 3). If such hotspots are successfully identified (see
details in “Methods”), the sequence of the gene is di-
vided into fragments; otherwise its entire exome is in-
cluded within the panel. Including mutational hotspots
rather than the entire sequence of genes contributes to
minimize the quantity of DNA in the panel. Next, it
builds the cumulative distribution of mutations observed
across tumors of the panel cohort sorting all genes and/
or hotspots in the process. The shape of the resulting cu-
mulative distribution and the ranking of genes and/or hot-
spots is then employed to select the ones that actually
increase the fraction of mutated samples of the panel co-
hort that would be identified by the panel, hence coverage.
Selected genes and/or hotspots are divided in two tiers de-
pending on their contribution to this coverage. Finally,
OncoPaD reports back to the researcher the list of both
tiers of genes and/or hotspots, with their individual contri-
bution to the coverage and the base pairs (bps) of DNA
that each would add to the panel (Fig. 1, panel 5). The re-
ports also include details, such as the distribution of muta-
tions across the sequence of each item, and a trove of
manually collected information of each individual muta-
tion observed in the panel cohort, including their known
oncogenic potential, or their effect on tumor response to
therapies. Several elements along the design process may
be fine-tuned by the user to refine the design of the panel
(see details in use cases available at http://www.intogen.
org/oncopad/case_studies).
To our knowledge, only three other approaches (Table 1)
provide the users certain support to design cancer gene
panels: (1) TEAM [15], a tool which supports the design
of panels for a number of diseases based on pathogenic
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Fig. 1 Illustration of the rationale of OncoPaD and its use. Left: Information required to start the design of a panel. It consists of two mandatory
parameters: (1) cancer type(s) of the panel (top) and (2) genes of interest: (a) cancer driver genes (CDs), (b) CDs with drug biomarkers, or (c) a list
provided by the user (middle). Some advanced parameters are configurable to design the panel (bottom). Right: OncoPaD algorithm. OncoPaD
filters a pan-cancer cohort (7298 samples) by the cancer type(s) selected by the user (1), thus producing the cohort relevant for the panel; next,
the genes relevant to tumorigenesis in the panel cohort are chosen from those selected by the user (2); the mutational hotspots of these genes
are identified (details in Additional file 2: Figure S1 and the "Methods" section) (3); the cumulative distribution of mutations (or coverage) of
selected genes and/or hotspots in the panel cohort is built and those that contribute the most to this coverage (Tiers 1 and 2) are selected (4);
finally OncoPaD generates reports of the main features of the designed panel, with additional ancillary information of all genes and/or mutational
hotspots in the panel (5)
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variants with high functional impact collected from four
different databases (see Aleman et al. [15] for more details
on the method); (2) the approach proposed by Martinez et
al. [16] to design cancer gene panels based on recurrent
non-synonymous mutations across TCGA cohorts; and (3)
the DesignStudio tool by Illumina Inc. (www.illumina.com/
designstudio), which determines the primers and genomic
coordinates of a panel designed from user provided genes.
The first unique characteristic of OncoPaD, when com-
pared to these tools, is the possibility of basing the de-
sign of the panels on the list of drivers acting in (or
biomarkers of drug response relevant to) specific tumor
types. This feature renders OncoPaD designed panels
uniquely suitable to screen cancer cohorts, unlike those
based on methods (1) and (2), whose performance is ex-
pected to be affected because not all recurrently mutated
or high impacting mutated genes are relevant for cancer
development, and many oncogenic mutations are known
to have a low functional impact. Furthermore, OncoPaD
is the only tool that conducts the fine-tuning of the panel
based on its in silico cost-effectiveness (see below). It is
also highly configurable and the reports generated include
ancillary information which guide researchers in the inter-
pretation of the results obtained on its application to a co-
hort of tumor samples.
Note that OncoPaD, as TEAM [15] and the approach
presented by Martinez et al. [16], aims to design gene
panels to detect exclusively protein-coding point muta-
tions and small indels. This is a limitation of the three
methods, since copy number alterations, translocations,
and non-coding mutations, which may be relevant for
cancer development and the response to anti-cancer treat-
ments, are not targeted for detection. This is the result of
several decades of research on cancer overwhelmingly fo-
cused on the relevance of coding point mutations. As more
information on other driver alterations—in particular aris-
ing from the analysis of tumor whole-genomes—becomes
available, we will include it within OncoPaD to support the
design of more comprehensive cancer gene panels.
OncoPaD designs highly cost-effective panels
We compared the cost-effectiveness of OncoPaD designed
panels to that of several available panels in three research
scenarios. To carry out the comparisons, we first defined
(and computed in silico) the cost-effectiveness of a gene
panel as the balance between the fraction of samples of a
cohort with mutations in genes contained in it (coverage),
and the total DNA amount (Kbps). We used this in
silico representation as a proxy of the real-life cost-
effectiveness of a gene panel.
We first compared the cost-effectiveness of OncoPaD
panels and 13 widely-employed panels, including the
TruSight Amplicon Cancer Panel provided by Illumina,
the Gene Read DNAseq Targeted Panels v2 from QIA-
GEN and the xGen® Pan-Cancer Panel of Integrated
DNA Technologies, the only one including in its design
a list of cancer driver genes [17] on a ~7000 tumors
pan-cancer cohort (Fig. 2a, Additional file 4: Table S3A).
In the coverage versus DNA amount space presented in
Fig. 2a, the closer a panel (individual circles) is to the
top right corner, the higher its coverage of mutated tu-
mors in the cohort and the lower its content of DNA and,
Table 1 Comparison of OncoPaD with other resources. Six different features are included: (1) the input genes for panel design; (2)
whether the resource allows to estimate (and fine-tune) the cost-effectiveness of the designed panel; (3) whether the resource pro-
vides additional ancillary annotations for mutations included in the panel; (4) whether the tool is a web service easy to maintain,
evolve and use or a static resource; (5) the type of output provided to the user; and (6) the level of customization of the panel that
the user can attain
TEAM [15] Martinez et al. [16] Design studio OncoPaD
Input genes • Genes with HIMs from
COSMIC
• User’s mutation list
Genes with NSMs in at least
4 % of samples in cohort 1
User’s gene list • Driver genes in 28 cancer types
• Genes with drug biomarkers
• User’s gene list
In silico
performance




• Fraction of tumors from cohort 2 with PAMs





• Validated oncogenic mutations
• Drug biomarker mutations
Type of resource Web service Static panels Web service Web service
Output Json file with selection
of genes
List of ranked pan-cancer
and per cancer type genes
• Bed file
• Panel primers
• Reports with information on mutations included




• Filter by genes with
HIMs
• Filter by genes found in
COSMIC
• Add/remove genes
Input gene list • Cancer type(s) to design the panel
• Panel input genes (pre-compiled lists of drivers/
biomarkers and/or user defined).
• Fine-tune the design of the panel
cohort 1: 3192 samples from ten cancer types; cohort 2: 7298 samples from 28 cancer types
HIM high impacting mutation, PAM protein-affecting mutation, NSM non-synonymous mutation
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therefore, the higher its cost-effectiveness. For example,
the MSK-IMPACT panel would achieve the highest cover-
age (90 %), but at the cost of sequencing 1030 Kbps of
DNA from each sample. The Comprehensive Cancer Panel
(Ion AmpliSeq™) and the Pan-cancer (FoundationOne®)
panels would attain 84 % and 80 % coverage by
sequencing 1130 and 634 Kbps of DNA, respectively. On
the other hand, an OncoPaD designed panel for all cancer
types including Tier 1 genes and hotspots would achieve
79 % coverage, but sequencing only 355 Kbps of DNA,
roughly half of that sequenced by the latter and less than




Fig. 2 Cost-effectiveness of OncoPaD and widely employed panels. a Cost-effectiveness of pan-cancer panels. The bubble plot presents in the
x-axis the cohort coverage of each panel—i.e. proportion of samples of the pan-cancer cohort mutated in genes and/or hotspots of the
panel—versus the amount of DNA (Kbps) included in each panel (y-axis). The size of the bubbles represents the proportion of genes in
the panel that are cancer driver genes according the four lists integrated in OncoPaD (see “Methods”). Red bubbles correspond to OncoPaD panels
focused on drug profiling, i.e. considering as input driver genes drug biomarkers; blue bubbles are OncoPaD panels based on driver genes; gray bubbles
represent other widely employed panels. b Cost-effectiveness of panels in the evaluation of solid tumors. c Cost-effectiveness of cancer type-specific
panels. OncoPaD panels fine-tuned for glioblastoma (pale green area), breast cancer (pale red area), and colorectal cancer (pale yellow area) were built
and assessed in comparison to four pan-cancer and one solid tumor-specific widely employed panels. All data on coverage and DNA amount used to
build these graphs is available in Additional file 4: Table S3
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effectiveness (blue circles). If the task at hand was the de-
sign of a panel to screen the same pan-cancer cohort for
known targetable mutations (within our in-house database
of biomarkers; see “Methods” for details), the highest cost-
effectiveness would correspond to an OncoPaD designed
panel including hotspots for drug profiling (Tiers 1 and
2), where the starting list of genes is specifically selected
for mutations that influence the effect of a drug. Such a
panel would cover 68 % of the pan-cancer samples se-
quencing only 83 Kbps of DNA (red circles).
We speculated that the cost-effectiveness of OncoPaD
panels should increase the more homogeneous the cohort
under screening is in terms of cancer types represented
because their design relies on tumor type specific drivers.
Therefore, we next compared the cost-effectiveness of
OncoPaD and commercially available panels screening
only the subset of solid tumors within the pan-cancer
cohort (Fig. 2b, Additional file 4: Table S3B). Here, the
advantage of OncoPaD panels among all those evaluated
is more apparent. Specifically, an OncoPaD hotspots
(Tier 1) designed panel would cover the highest fraction
of solid tumors in the cohort (83 %), sequencing only 291
Kbps of DNA. To stratify solid tumors potentially respon-
sive to anti-cancer agents, three OncoPaD designs would
provide information about all tumors in the cohort,
followed by the OncoVantage Solid Tumor Mutation Ana-
lysis (Quests diagnostics) (97 %). Finally, we compared the
cost-effectiveness of panels in screening tumor type-
specific cohorts (Fig. 2c, Additional file 4: Table S3C).
While all assayed panels would detect between three-
quarters and four-fifths of breast carcinomas, between
three-quarters and nine-tenths of glioblastomas and virtu-
ally all colorectal adenocarcinomas, OncoPaD designed
panels would do that by sequencing a dramatically smaller
amount of DNA. For instance, the Comprehensive Cancer
Panel (Ion AmpliSeq™) panel would cover 99 % of the
tumors in the colorectal cohort, sequencing 862.21
Kbps of DNA, compared to 97 % with 21.61 Kbps of DNA
(40 times less) of an OncoPAD whole genes Tier 1 panel,
consequently increasing the number of samples that can
be analyzed in parallel and/or increasing sequencing
coverage. It is also important to bear in mind that while
the genes in all OncoPaD panels are drivers of each tumor
types, other panels include genes which are not implied in
tumorigenesis in the tumor type(s) of the panel cohort (or
any tumor type) and may lead to the detection of false
positives. This would increase their likelihood of detecting
false-positive mutations (either germline or somatic unre-
lated to tumorigenesis) [3], a feature which may turn key
when the material sequenced comes from a paraffin-fixed
sample with no normal DNA to filter the variants in the
patient’s genome.
Additionally, we assessed the cost-effectiveness of
available solid tumor panels (see above) and OncoPaD
solid tumors panels on a cohort of cervical and endocer-
vical cancer which is not currently included in the
OncoPaD pan-cancer cohort (Additional file 2: Figure
S2), to assess the capacity of extrapolation of the
catalog of driver genes included in the tool to novel
not covered cancer types. An OncoPaD panel of Tier 1
genes exhibited the highest cost-effectiveness, with the
Centrogene panel producing a greater coverage of the
tumors of the cohort, but at the expense of sequencing
four times more DNA. Note that OncoPaD will be con-
tinuously updated as new sequenced tumor cohorts and
lists of novel cancer driver genes and drug biomarkers
become available.
In summary, OncoPaD designed panels present better
cost-effectiveness than their currently available counter-
parts. Furthermore, the availability of several lists of
genes relevant to tumorigenesis in different cancer types
or specifically informative of the response to anti-cancer
drugs provides them a unique versatility with respect to
available one-size-fits-many solutions.
Use case: designing a panel with OncoPaD to screen the
drug response of a cohort of lung carcinomas
OncoPaD will help clinicians and researchers design
NGS panels to detect circulating tumor DNA or bi-
opsy specimens, thereby facilitating early and accurate de-
tection of tumors, genomics informed therapeutic decisions
and patient follow-up, with timely identification of re-
sistance mechanisms to targeted agents (researchers
dealing with studies as the ones exemplified in the
“Background” section constitute the natural users of
OncoPaD). We illustrate its use in three specific real-
life research questions through tutorials available at http://
www.intogen.org/oncopad/case_studies.
In this section, we briefly present one of them, the use
of OncoPaD for the design of drug screening panels for
lung carcinomas. First, a subset of tumors resulting from
pooling all lung carcinomas in the pan-cancer cohort is
selected to compute the panel cost-effectiveness and
lung cancer driver genes containing biomarkers of drug
response are selected to integrate it (Fig. 3a). Upon sub-
mitting this selection, the user obtains the cumulative
coverage of samples in the subset bearing mutations in
the genes and/or hotspots included in the panel, sorted
by their contribution (top panel Fig. 3b), here can ob-
serve how the panel generated covers 79 % of lung car-
cinomas including only 46.59 Kbps. He is also able to
visualize the actual distribution of mutational hotspots
in each gene in the panel. For example, as exempli-
fied in the middle panel of Fig. 3b, two mutational hot-
spots of EGFR contribute to the panel, although only one
of them is included in Tier 1. Furthermore, the bottom
panel of Fig. 3b provides a glimpse at the table where the
user finds further ancillary information on the relevance
Rubio-Perez et al. Genome Medicine  (2016) 8:98 Page 7 of 9
Fig. 3 Designing a panel to screen the response to drugs of a cohort of lung carcinomas. a Input required by OncoPaD to design the panel.
b Simplified illustration of panel reports. From top to bottom: (1) cumulative coverage of Tier 1 panel candidates in all lung carcinomas (black line)
and coverage in each individual cohort of lung tumors included in the panel cohort (blue, yellow, pale brown, and green lines); (2) needle plot of the
number of protein affecting mutations found along the sequence of one of Tier 1 candidates (EGFR) (green and violet needles), hotspots appear as
black rectangles on the x-axis; and (3) annotation of drug response and oncogeneicity of gene panel mutations in the hotspot of EGFR exon 21.
c Available format to download OncoPaD panel details: BED file, Excel file or PDF
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of individual mutations in oncogenesis or influencing drug
response. Finally, the designed panel can be downloaded
as a BED file, an Excel file with multiple sheets or a
PDF file with the complete HTML report (Fig. 3c).
Conclusions
We have presented OncoPaD, to our knowledge the first
tool aimed at the rational design of cancer gene panels. The
estimated cost-effectiveness of OncoPaD designed panels
surpasses that of their currently available counterparts. The
intuitive design and versatility of the tool will aid clinicians
and researchers in the design of panels to address a variety
of translational and basic research questions.
Additional files
Additional file 1: Description of tumor cohorts. Excel file with
description of the mutational datasets currently used by the
OncoPaD web service (Table S1). (XLSX 6 kb)
Additional file 2: Supplementary Data. PDF file containing the headers
and legends of Tables S1–S3, Figures S1 and S2, and Supplementary
Methods. (PDF 421 kb)
Additional file 3: Drivers information. Excel file containing the list of
driver genes per tumor type currently used by the OncoPaD web service
(Table S2). (XLSX 44 kb)
Additional file 4: Comparison with commercial panels. Excel file
containing the results of the comparison of gene panels designed
employing OncoPaD with commercially available panels (Table S3).
(XLSX 34 kb)
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